Brief: Marker Therapeutics Announces FDA Clearance Of Ind For MT-601, Its Six-Antigen T Cell Therapy For The Treatment Of Pancreatic Cancer
22/11/2022 12:21
Nov 22 (Reuters) - Marker Therapeutics Inc MRKR.O :
* MARKER THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND FOR
MT-601,
ITS SIX-ANTIGEN T CELL THERAPY FOR THE TREATMENT OF PANCREATIC
CANCER
Source text for Eikon: ID:nGNX5rDM47
Further company coverage: MRKR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Marker Therapeutics
See all newsBrief: Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant To Advance MT-601 In Pancreatic Cancer
Marker Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Marker Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
Marker Therapeutics 2025 net loss widens, hurt by decline in grant income
Brief: Marker Therapeutics FY Basic EPS USD -0.79